Celexion LLC

BioAmber and CELEXION Announce Exclusive Licensing Partnership

BioAmber and CELEXION Announce Exclusive Licensing Partnership

March 15, 2011

MINNEAPOLIS, MN, March 15 /PRNewswire/ - BioAmber, the market leader in biobased succinic acid, has entered into an exclusive licensing agreement with CELEXION LLC for technology related to the production of adipic acid and other chemical intermediates. The current market for adipic acid is close to 3 million tons per year, worth approximately $8 billion at current market prices.

Flagship's Noubar Afeyan quoted in New York Times story, "Alt-Fuel Hopefuls Make Plays for Oil Companies' Cash"

Flagship's Noubar Afeyan quoted in New York Times story, "Alt-Fuel Hopefuls Make Plays for Oil Companies' Cash"

March 11, 2011

 "...Joule Unlimited of Cambridge, Mass., introduced potential investors here to a process they say can convert sunlight directly into diesel fuel through specially cultured microorganisms."

Click NY Times logo to view entire article.

MIT’s Technology Review Unveils 2011 TR50 List of the World’s Most Innovative Companies

MIT’s Technology Review Unveils 2011 TR50 List of the World’s Most Innovative Companies

February 22, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Technology Review today announced the 2011 TR50, the second annual list of the world’s most innovative technology companies. In selecting the TR50, the editors of Technology Review look for companies that are setting the agenda in an increasingly important market, on the verge of disrupting an established market, or creating an entirely new market. Spanning energy, computing, the Web, biomedicine, and materials, the companies on the list are using their inventions to reshape their industries and to transform how we live.

Quanterix Corporation

Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability

Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability

February 23, 2011

CAMBRIDGE, MA – February 23, 2011– Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company’s Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement.

Quanterix Corporation

Quanterix Announces New Technology Evaluation Agreement

Quanterix Announces New Technology Evaluation Agreement

February 22, 2011

CAMBRIDGE, MA – February 22, 2011 – Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix’s SiMoA platform technology for diagnostic use. The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.

Flagship VentureLabs, Creating and Spinning Out Cleantech and Life Sciences Startups for 10 Years, Takes the Veil Off

Flagship VentureLabs, Creating and Spinning Out Cleantech and Life Sciences Startups for 10 Years, Takes the Veil Off

Joule Unlimited, Inc.

Joule on Pace to Produce Solar Fuels at Productivities Far Exceeding Those of All Known Biofuel Processes

Joule on Pace to Produce Solar Fuels at Productivities Far Exceeding Those of All Known Biofuel Processes

February 17, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today supported the high-productivity potential of its production process with the publication of a detailed analysis and model of its breakthrough solar-to-fuels platform.

BG Medicine, Inc.

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

February 16, 2011

WALTHAM, Mass., Feb. 16, 2011 (GLOBE NEWSWIRE) -- BG Medicine (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers, today announced the issuance of U.S. Patent No. 7,888,137, entitled "Method For Identifying a Subject at Risk of Developing Heart Failure by Determining the Level of Galectin-3 or Thrombospondin-2" to the University of Maastricht. BG Medicine has an exclusive license to this issued patent, which pertains to galectin-3 testing for individuals at risk for heart failure.

AVEO Pharmaceuticals, Inc.

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

February 16, 2011

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, “Astellas”), a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO, “AVEO”) today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

BG Medicine, Inc.

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

February 9, 2011

WALTHAM, Mass.--(BUSINESS WIRE)-- BG Medicine (NASDAQ: BGMD) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.